AstraZeneca is one of the world's leading biopharmaceutical companies, founded in the UK in 1999. The main activity of the company is the development of drugs for the treatment of orphan diseases. The company has accumulated extensive experience in this field, mainly through drugs for the treatment of autoimmune and neuropathic pain. The company also offers modern therapeutic solutions that improve the quality of life of patients.

The Foundation's management, together with representatives of AstraZeneca, A. Teteryuk and I. Litus, exchanged views on the timely supply of medicines to children with orphan diseases registered in Uzbekistan, establishing bilateral cooperation to ensure their quality of life, as well as training doctors to diagnose the disease.

Representatives of the company, in turn, expressed their proposals for cooperation with the Public Foundation and reached an agreement.